The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AMPH | -35.76% | +15.4% | +2.9% | +102% |
| S&P | +17.36% | +80.49% | +12.52% | +251% |
Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
Amphastar is down big in 2025, but recently announced positive FDA-related news.
Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $183.11M | -1.8% |
| Gross Profit | $81.86M | -1.8% |
| Gross Margin | 44.70% | 0.0% |
| Market Cap | $1.23B | -31.1% |
| Market Cap / Employee | $622.77K | 0.0% |
| Employees | 2K | -2.6% |
| Net Income | $24.43M | -35.7% |
| EBITDA | $51.59M | -13.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $170.41M | 12.2% |
| Accounts Receivable | $143.56M | 5.3% |
| Inventory | 176.9 | 15.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $646.43M | 0.5% |
| Short Term Debt | $9.57M | 36.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 5.94% | -4.2% |
| Return On Invested Capital | 9.77% | 0.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $24.59M | 48.0% |
| Operating Free Cash Flow | $32.86M | 13.2% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 10.52 | 8.60 | 11.82 | 13.17 | 8.65% |
| Price to Book | 1.89 | 1.46 | 1.64 | 1.60 | -35.26% |
| Price to Sales | 1.98 | 1.53 | 1.76 | 1.75 | -32.59% |
| Price to Tangible Book Value | 9.75 | 6.56 | 6.92 | 6.07 | -55.10% |
| Price to Free Cash Flow TTM | 9.63 | 9.85 | 11.22 | 10.42 | -5.75% |
| Enterprise Value to EBITDA | 35.42 | 26.13 | 40.13 | 31.67 | -18.77% |
| Free Cash Flow Yield | 10.4% | 10.2% | 8.9% | 9.6% | 6.10% |
| Return on Equity | 19.9% | 18.3% | 14.8% | 12.9% | -44.55% |
| Total Debt | $652.53M | $655.50M | $656.77M | $656.00M | 0.84% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
